题目一：Writing and reviewing technical manuscripts: best practices
题目二：Combination devices: implants that release drugs
时 间：2010年11月2日14:00-18:00
地 点：高分子楼二楼学术报告厅（228房间）
邀请人：计 剑 教授
David W. Grainger教授简介：
David W. Grainger，犹他大学药学与药物化学系主任，生物工程系教授。1987年获得犹他大学药物化学博士学位，后赴德国美因茨大学在Helmut Ringsdorf组从事博士后研究。其研究领域包括聚合物生物材料与细胞的相互作用，医疗器械感染和细菌定植，核酸和蛋白质芯片性能，巨噬细胞和生物材料的相互作用，新型活性疫苗和蛋白质的传递以及生物分析检测和设备的小型化等。目前已在Nat. Nanotechnol, J. Am. Chem. Soc., Adv. Mater., Adv. Drug. Deliv. Rev., Anal. Chem., Biomaterials等杂志发表文章130余篇。
David W. Grainger教授现为美国科学促进会会士，美国医学和生物工程学会会士，并于2008年荣膺国际生物材料科学与工程联合会荣誉会士。他曾组织过21次与生物材料相关的国际学术会议，并担任四种生物材料领域重要杂志的编委，每年审稿超过50篇。
报告内容：
Title: 1. Writing and reviewing technical manuscripts: best practices
Abstract:
Despite superior data quality, writing a good quality scientific manuscript will improve its chances for acceptance and publication. Scientific writing can be learned; effective communication does not occur without training and experience. Gaining that experience is often a trial-and-error process, but it should not be. There are many resources and methods available in the open literature to formulate and produce a focused, effective scientific manuscript.
By contributing a manuscript to a peer-reviewed journal, the authors have burdened the scientific publishing system. The proper responsibility and respect for the peer-review system is to compensate for this burden by reviewing other’s manuscripts promptly, competently and thoroughly in turn. Reviewing a manuscript can be just as difficult as writing one: criticizing others’ work must be carefully, ethically and fairly pursued. The process of peer review is important to learn if one is also submitting papers. Editors count on authors to contribute their critical expertise fully to enforcing the qualities of peer review. This is a talent that can be learned.
References:
D.W. Grainger, Biomaterials. 28 5199-5203 (2007); D.W. Grainger, Revista Ingeniria Biomedica, 3(5) 66-73 (2009).
Title 2. Combination devices: implants that release drugs
Abstract:
Combination devices -- those comprising drug-releasing components together with functional prosthetic implants -- represent a versatile, emerging clinical technology promising to provide functional improvements to implant devices in several classes. Landmark anti-microbial catheters and the drug-eluting stent have heralded the entrance, and significantly, routes to FDA approval, for these devices into clinical practice. This talk will review recent strategies creating implantable combination medical devices. Most prominent are new combination devices representing current orthopedic and cardiovascular implants with new added capabilities from on-board or directly associated drug delivery systems are now under development. Wound coverings and implantable sensors will also benefit from this combination enhancement. Infection mitigation, a common problem with implantable devices, is a current primary focus. On-going progress in cell-based therapeutics, progenitor cell exploitation, growth factor delivery and advanced formulation strategies will provide a more general and versatile basis for advanced combination device strategies. These seek to improve tissue-device integration and functional tissue regeneration. Future combination devices might best be completely re-designed de novo to deliver multiple bioactive agents over several spatial and temporal scales to enhance prosthetic device function, instead of the current 'add-on' approach to existing implant device designs never originally intending to function in tandem with drug delivery systems.
References:
P. Wu, D.W. Grainger, “Drug/Device Combinations for Local Drug Therapies and Infection Prophylaxis,” Biomaterials 27, 2450-2467 (2006); H. Takahashi, D. Letourneur, D.W. Grainger, “Delivery of large biopharmaceuticals from cardiovascular stents: a review” Biomacromolecules, 10.1021/bm700540p, 8(11) 3281-3293 2007.
|
